Uveitis

Deschenes J, Murray PI, Rao NA, et al; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2. Abstract

Jabs DA, Nussenblatt RD, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Abstract

Kempen JH, Altaweel MM, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26.Full text  Abstract

1. Deschenes J, Murray PI, Rao NA, et al; International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2. Abstract

2. Jabs DA, Nussenblatt RD, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Abstract

3. Miserocchi E, Fogliato G, Modorati G, et al. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013 Sep-Oct;23(5):705-17. Abstract

4. García-Aparicio Á, García de Yébenes MJ, Otón T, et al. Prevalence and incidence of uveitis: a systematic review and meta-analysis. Ophthalmic Epidemiol. 2021 Feb 8;:1-8. Abstract

5. Silverstein A. Changing trends in the etiologic diagnosis of uveitis. Doc Ophthalmol. 2005 Sep;140(3):509-16. Abstract

6. Gritz DG, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004 Mar;111(3):491-500. Abstract

7. Baarsma GS. The epidemiology and genetics of endogenous uveitis: a review. Curr Eye Res. 1992;11 suppl:1-9. Abstract

8. Biswas J, Narain S, Das D, et al. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol. 1996-1997;20(4):223-8. Abstract

9. Merrill PT, Kim J, Cox TA, et al. Uveitis in the southeastern United States. Curr Eye Res. 1997 Sep;16(9):865-74. Abstract

10. Barisani-Asenbauer T, Maca SM, Mejdoubi L, et al. Uveitis - a rare disease often associated with systemic diseases and infections - a systematic review of 2619 patients. Orphanet J Rare Dis. 2012 Aug 29;7:57.Full text  Abstract

11. Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2-16. Abstract

12. Murray CJ, Ortblad KF, Guinovart C, el al; GBD Study group. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):1005-70.Full text  Abstract

13. Radosavljevic A, Agarwal M, Chee SP, et al. Epidemiology of viral induced anterior uveitis. Ocul Immunol Inflamm. 2021 Feb 22;1-13. Abstract

14. Lee JH, Agarwal A, Mahendradas P, et al. Viral posterior uveitis. Surv Ophthalmol. 2017 Jul-Aug;62(4):404-45.Full text  Abstract

15. Jackson TL. Moorfields manual of ophthalmology. 3rd ed. London: Jaypee Brothers Medical Publishers; 2019.

16. McCluskey PJ, Towler HM, Lightman S. Management of chronic uveitis. BMJ. 2000 Feb 26;320(7234):555-8.Full text  Abstract

17. Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000 Dec;8(4):251-61. Abstract

18. American Society for Clinical Pathology. Thirty five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].Full text

19. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58. Abstract

20. Colucciello M. Ocular Lyme borreliosis. N Engl J Med. 2001 Nov 1;345(18):1350-1. Abstract

21. Margolis R, Brasil OF, Lowder CY, et al. Vitrectomy for the diagnosis and management of uveitis of unknown cause. Ophthalmology. 2007 Oct;114(10):1893-7. Abstract

22. Ahram DF, Alward WL, Kuehn MH. The genetic mechanisms of primary angle closure glaucoma. Eye (Lond). 2015 Oct;29(10):1251-9.Full text  Abstract

23. Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002 Feb;46(2):309-18. Abstract

24. Gui W, Dombrow M, Marcus I, et al. Quality of life in patients with noninfectious uveitis treated with or without systemic anti-inflammatory therapy. Ocul Immunol Inflamm. 2015 Apr;23(2):135-43. Abstract

25. Lemley C, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007 Jul-Aug;27(6):662-80. Abstract

26. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006 Jun;113(6):1020-7. Abstract

27. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018 May;125(5):757-73.Full text  Abstract

28. Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019 Sep 10;322(10):936-45.Full text  Abstract

29. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019 Apr;23(15):1-140.Full text  Abstract

30. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43.Full text  Abstract

31. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183-92. Abstract

32. National Institute for Health and Care Excellence (UK). Adalimumab and dexamethasone for treating non-infectious uveitis. 26 July 2017 [internet publication].Full text

33. Boiten HJ, Amini S, Wolfhagen FHJ, et al. Adalimumab-induced platelet antibodies resulting in severe thrombocytopenia. Br J Clin Pharmacol. 2021 Feb 18 [Epub ahead of print]. Abstract

34. Durrani K, Zakka FR, Ahmed M, et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011 Nov-Dec;56(6):474-510. Abstract

35. Kempen JH, Altaweel MM, Holbrook JT, et al; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26.Full text  Abstract

36. Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev. 2016 Feb 12;(2):CD010469.Full text  Abstract

37. Kempen JH, Altaweel MM, Holbrook JT, et al; Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017 May 16;317(19):1993-2005. Abstract

38. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018 Aug;77(8):1107-17.Full text  Abstract

39. Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019 Aug;49(1):43-55.Full text  Abstract

40. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2019 Jun;71(6):703-16.Full text  Abstract

41. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017 Apr 27;376(17):1637-46.Full text  Abstract

42. Chiam NP, Lim LL. Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol. 2014;2014:401915.Full text  Abstract

43. Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017 Aug;43(3):489-502.Full text  Abstract

44. Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study. PLoS One. 2019;14(10):e0223603.Full text  Abstract

45. Maya JR, Sadiq MA, Zapata LJ, et al. Emerging therapies for noninfectious uveitis: what may be coming to the clinics. J Ophthalmol. 2014 Apr 24;2014:310329.Full text  Abstract

46. De Benedetti F, Brunner HI, Ruperto N, et al; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012 Dec 20;367(25):2385-95.Full text  Abstract

47. Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020 Mar;2(3):e135-41.Full text  Abstract

48. Jackson ML, Virgili G, Shepherd JD, et al. Vision rehabilitation preferred practice pattern®. Ophthalmology. 2023 Mar;130(3):P271-335.Full text  Abstract

49. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785-96;e3. Abstract

50. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332-6.Full text  Abstract

51. Gopalakrishnan S, Sudharshan S, Raman R, et al. Visual rehabilitation of patients with low vision in uveitis. Indian J Ophthalmol. 2019 Jan;67(1):101-4.Full text  Abstract